Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis
- PMID: 35739381
- DOI: 10.1007/s13304-022-01309-2
Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis
Abstract
To date, there is little knowledge about the value of laparoscopic liver resection (LLR) for hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer (BCLC) stage B. Thus, this study was performed to assess the perioperative and oncological outcomes of LLR for these patients by comparison with open liver resection (OLR). Between April 2015 and October 2018, a total of 217 resectable HCC patients with BCLC stage B were eligible for this study. Patients were divided into the LLR group and the OLR group according to different procedures. Propensity score matching (PSM) was conducted to adjust for known confounders. Short- and long-term outcomes were compared between the two groups. LLR was performed in 75 of the 217 included patients. After PSM, 72 patients with well-balanced baseline levels were enrolled into each group. Although the operative time was significantly longer in the LLR group than in the OLR group (median, 237.5 vs. 210 min, P = 0.024), the intraoperative blood loss was significantly less in the LLR group than in the OLR group (median, 200 vs. 350 ml, P = 0.005). Patients in the LLR group had fewer complications than those in the OLR group (P = 0.035). Furthermore, overall survival (OS, P = 0.827) and recurrence-free survival (RFS, P = 0.694) were comparable between the two groups. LLR for resectable HCC patients with BCLC stage B is safe and feasible in carefully selected patients and has superior perioperative outcomes and similar survival rates compared with OLR.
Keywords: BCLC stage B; Hepatocellular carcinoma; Laparoscopic hepatectomy; Open hepatectomy; Short-term outcomes; Survival rate.
© 2022. Italian Society of Surgery (SIC).
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314. https://doi.org/10.1016/s0140-6736(18)30010-2 - DOI - PubMed
-
- Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35:2155–2166. https://doi.org/10.1111/liv.12818 - DOI - PubMed - PMC
-
- European association for the study of the L, European organisation for R, treatment of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 56:908–943. https://doi.org/10.1016/j.jhep.2011.12.001 - DOI
-
- Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A et al (2021) BCLC strategy for prognosis prediction and treatment recommendation barcelona clinic liver cancer (BCLC) staging system The 2022 update. J Hepatol. https://doi.org/10.1016/j.jhep.2021.11.018 - DOI - PubMed
MeSH terms
Grants and funding
- No. 81602910/National Natural Science Foundation of China
- No. 81302344/National Natural Science Foundation of China
- No. 81802095/National Natural Science Foundation of China
- Nos. 2019YFS0370/Department of Science and Technology of Sichuan Province
- 2019YFS0372/Department of Science and Technology of Sichuan Province
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
